The first cancer drug with no meaningful adverse effects.
We are a Swiss company founded 2019 in Zug, with a patented (pend) method to reverse carcinogenesis. Operations to be started in NYC and Florida with local investors.
In preclinical trials, CRB091 worked against deadly cancers, such as colorectal cancer, pancreatic cancer, and triple-negative breast cancer. It has been shown to reduce side effects of chemotherapy, and add to its efficacy. Entering patients in 2 years after an extensive regulatory process, for which we seek funding, first step 500k Euros as a SAFE note (if EUR Convertible Note), total need 5M to first in-human permission.
Unique innovation:
CRB091 affects cancer where it really comes from, the metabolic failures, restoring mitochondrial functions.
De-risked: the drug candidate CRB091 is a combination of two non-toxic efficacious active ingredients, and therefore, we have been able to establish both efficacy AND safety already at this stage, based on human studies on both APIs. A fast track leads to patients in just two years.
The team is lean, and consists of experienced leaders in life science, finance, and scientists. An extensive network of advisors, all professor level, have helped develop the drug candidate. There is a dramatic value increase ahead going to human use.
Available to discuss the very rational science and plans anytime! Main location Zug, Switzerland. CEO Mr. Kari Sarvanto, mobile: +41 796 162 694, email:
[email protected]